Research analysts at StockNews.com started coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a report released on Monday. The firm set a "buy" rating on the medical instruments supplier's stock.

Pro-Dex Stock Performance

PDEX opened at $17.15 on Monday. The stock's 50 day simple moving average is $16.93 and its 200 day simple moving average is $17.40. The stock has a market cap of $61.40 million, a P/E ratio of 16.49 and a beta of 0.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.73 and a quick ratio of 1.39. Pro-Dex has a 1-year low of $12.40 and a 1-year high of $26.50.

Get Pro-Dex alerts:

Pro-Dex (NASDAQ:PDEX – Get Rating) last announced its earnings results on Thursday, November 3rd. The medical instruments supplier reported $0.29 EPS for the quarter. The firm had revenue of $11.09 million for the quarter. Pro-Dex had a return on equity of 16.75% and a net margin of 8.97%.

Institutional Investors Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its holdings in Pro-Dex by 345.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock valued at $48,000 after buying an additional 2,084 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Pro-Dex during the 2nd quarter valued at $168,000. State Street Corp grew its holdings in Pro-Dex by 5.8% during the 1st quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock valued at $197,000 after buying an additional 650 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Pro-Dex by 59.2% during the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock valued at $345,000 after buying an additional 7,762 shares during the last quarter. Finally, LSV Asset Management grew its holdings in Pro-Dex by 13.9% during the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock valued at $588,000 after buying an additional 4,346 shares during the last quarter. Institutional investors and hedge funds own 13.49% of the company's stock.

About Pro-Dex

(Get Rating)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Recommended Stories

• Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
• General Electric Stock, The Sum of All Parts Strategy is Paying Off
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.